The Supreme Court is due to hear arguments today on whether it's possible to patent isolated human genes in a debate that encompasses the concept that IP can't cover "laws of nature." The case involves Myriad Genetics (MYGN), which holds two patents that allow it to genetically screen those at risk of breast or ovarian cancer. The impact of any ruling on the human-gene field will probably be limited, although it could have ramifications for the wider pharmaceuticals sector, agriculture, industrial microbiology and alternative fuels.
The Supreme Court is due to hear arguments today on whether it's possible to patent isolated...
From other sites
Video at CNBC.com (Sep 15, 2015)
at CNBC.com (Oct 17, 2014)
at CNBC.com (Aug 13, 2014)
at CNBC.com (Aug 12, 2014)
at CNBC.com (Apr 11, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs